Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 43 | 2020 | 1135 | 6.720 |
Why?
|
| Brain Ischemia | 32 | 2019 | 403 | 5.990 |
Why?
|
| Neuroprotective Agents | 10 | 2016 | 72 | 2.080 |
Why?
|
| Tissue Plasminogen Activator | 8 | 2016 | 124 | 2.060 |
Why?
|
| Cerebrovascular Circulation | 13 | 2012 | 168 | 1.740 |
Why?
|
| Infarction, Middle Cerebral Artery | 7 | 2009 | 71 | 1.670 |
Why?
|
| Clinical Trials as Topic | 15 | 2016 | 435 | 1.660 |
Why?
|
| Periodicals as Topic | 4 | 2017 | 170 | 1.450 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 11 | 2009 | 141 | 1.440 |
Why?
|
| Thrombectomy | 3 | 2019 | 203 | 1.290 |
Why?
|
| Endovascular Procedures | 4 | 2019 | 556 | 1.180 |
Why?
|
| Fibrinolytic Agents | 5 | 2010 | 164 | 1.130 |
Why?
|
| Thrombolytic Therapy | 7 | 2016 | 180 | 1.020 |
Why?
|
| Editorial Policies | 2 | 2017 | 53 | 1.020 |
Why?
|
| Reperfusion Injury | 4 | 2016 | 51 | 0.920 |
Why?
|
| Disease Models, Animal | 14 | 2013 | 2042 | 0.900 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2009 | 248 | 0.890 |
Why?
|
| Ischemic Attack, Transient | 4 | 2018 | 90 | 0.800 |
Why?
|
| Rats | 17 | 2013 | 1901 | 0.740 |
Why?
|
| Time Factors | 16 | 2019 | 3544 | 0.680 |
Why?
|
| Reperfusion | 5 | 2010 | 37 | 0.670 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2009 | 2013 | 0.650 |
Why?
|
| Drug Design | 3 | 2010 | 143 | 0.640 |
Why?
|
| Treatment Outcome | 13 | 2020 | 5100 | 0.610 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 170 | 0.590 |
Why?
|
| Animals | 31 | 2016 | 19498 | 0.580 |
Why?
|
| Anticoagulants | 5 | 2020 | 485 | 0.570 |
Why?
|
| Brain | 7 | 2007 | 1475 | 0.550 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2006 | 180 | 0.510 |
Why?
|
| Warfarin | 3 | 2020 | 108 | 0.500 |
Why?
|
| Humans | 43 | 2020 | 58880 | 0.500 |
Why?
|
| Health Planning Guidelines | 2 | 2007 | 30 | 0.500 |
Why?
|
| Rats, Sprague-Dawley | 11 | 2008 | 569 | 0.480 |
Why?
|
| Ticlopidine | 2 | 2006 | 65 | 0.470 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2013 | 41 | 0.440 |
Why?
|
| Acute Disease | 8 | 2010 | 654 | 0.400 |
Why?
|
| Freezing | 1 | 2011 | 17 | 0.390 |
Why?
|
| Recovery of Function | 4 | 2019 | 262 | 0.380 |
Why?
|
| Embolism | 2 | 2008 | 37 | 0.370 |
Why?
|
| Thrombophilia | 1 | 2010 | 15 | 0.360 |
Why?
|
| Brain Injuries | 2 | 2013 | 140 | 0.350 |
Why?
|
| Aspirin | 2 | 2009 | 186 | 0.340 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 322 | 0.330 |
Why?
|
| Cerebral Infarction | 2 | 2007 | 75 | 0.330 |
Why?
|
| Male | 22 | 2019 | 27286 | 0.330 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2008 | 5 | 0.320 |
Why?
|
| Intracranial Embolism | 1 | 2009 | 39 | 0.320 |
Why?
|
| Research | 2 | 2009 | 190 | 0.320 |
Why?
|
| Gadolinium | 1 | 2009 | 98 | 0.320 |
Why?
|
| Brain Infarction | 1 | 2008 | 19 | 0.320 |
Why?
|
| Hyperoxia | 1 | 2008 | 15 | 0.320 |
Why?
|
| Behavior, Animal | 2 | 2007 | 214 | 0.310 |
Why?
|
| Biomedical Technology | 1 | 2007 | 6 | 0.280 |
Why?
|
| Contrast Media | 1 | 2009 | 405 | 0.280 |
Why?
|
| Atrial Fibrillation | 3 | 2020 | 794 | 0.280 |
Why?
|
| Cerebral Arteries | 1 | 2007 | 39 | 0.270 |
Why?
|
| Rats, Wistar | 4 | 2013 | 176 | 0.270 |
Why?
|
| Membrane Proteins | 1 | 2011 | 839 | 0.260 |
Why?
|
| Middle Cerebral Artery | 1 | 2006 | 45 | 0.260 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2005 | 16 | 0.250 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2005 | 96 | 0.250 |
Why?
|
| Device Approval | 1 | 2005 | 14 | 0.240 |
Why?
|
| Telemedicine | 2 | 2009 | 327 | 0.230 |
Why?
|
| Diffusion | 5 | 2008 | 84 | 0.230 |
Why?
|
| Cerebral Cortex | 1 | 2005 | 253 | 0.220 |
Why?
|
| Research Design | 2 | 2005 | 561 | 0.220 |
Why?
|
| Recombinant Proteins | 3 | 2016 | 688 | 0.220 |
Why?
|
| Patient Selection | 3 | 2016 | 440 | 0.220 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 211 | 0.210 |
Why?
|
| Stem Cell Transplantation | 1 | 2003 | 72 | 0.210 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 36 | 0.200 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2002 | 27 | 0.200 |
Why?
|
| Neurons | 2 | 2011 | 854 | 0.200 |
Why?
|
| Neuroimaging | 2 | 2013 | 130 | 0.190 |
Why?
|
| Heparin | 1 | 2002 | 113 | 0.190 |
Why?
|
| Blood Pressure | 3 | 2010 | 518 | 0.190 |
Why?
|
| Astrocytes | 1 | 2002 | 113 | 0.190 |
Why?
|
| Disease Management | 1 | 2003 | 219 | 0.190 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 5046 | 0.190 |
Why?
|
| Injections, Intravenous | 3 | 2006 | 146 | 0.180 |
Why?
|
| Drug Therapy, Combination | 3 | 2009 | 432 | 0.180 |
Why?
|
| Risk Factors | 4 | 2019 | 4975 | 0.180 |
Why?
|
| China | 1 | 2019 | 140 | 0.160 |
Why?
|
| Rivaroxaban | 1 | 2018 | 21 | 0.160 |
Why?
|
| Dabigatran | 1 | 2018 | 23 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 1446 | 0.160 |
Why?
|
| Risk Assessment | 2 | 2019 | 1893 | 0.150 |
Why?
|
| Disability Evaluation | 1 | 2019 | 214 | 0.150 |
Why?
|
| Aged | 6 | 2020 | 13221 | 0.140 |
Why?
|
| Regional Blood Flow | 2 | 2008 | 107 | 0.140 |
Why?
|
| Homes for the Aged | 1 | 2019 | 164 | 0.140 |
Why?
|
| Hemorrhage | 3 | 2019 | 276 | 0.140 |
Why?
|
| Secondary Prevention | 3 | 2018 | 151 | 0.140 |
Why?
|
| Protein C | 1 | 2016 | 30 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1020 | 0.140 |
Why?
|
| Nursing Homes | 2 | 2020 | 663 | 0.140 |
Why?
|
| Neurology | 1 | 2016 | 33 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 212 | 0.130 |
Why?
|
| Registries | 1 | 2019 | 800 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2016 | 134 | 0.130 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 1537 | 0.120 |
Why?
|
| Middle Aged | 4 | 2019 | 16134 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2009 | 662 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2020 | 5922 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 709 | 0.110 |
Why?
|
| Diagnostic Imaging | 2 | 2008 | 240 | 0.110 |
Why?
|
| Cerebral Hemorrhage | 2 | 2005 | 88 | 0.110 |
Why?
|
| United States | 5 | 2020 | 7441 | 0.110 |
Why?
|
| Language | 1 | 2014 | 138 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 541 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 2013 | 217 | 0.100 |
Why?
|
| Tetrazolium Salts | 2 | 2008 | 15 | 0.100 |
Why?
|
| Disks Large Homolog 4 Protein | 1 | 2011 | 19 | 0.100 |
Why?
|
| Vascular Surgical Procedures | 1 | 2013 | 244 | 0.090 |
Why?
|
| Factor V Deficiency | 1 | 2010 | 1 | 0.090 |
Why?
|
| Protein S Deficiency | 1 | 2010 | 1 | 0.090 |
Why?
|
| Protein C Deficiency | 1 | 2010 | 2 | 0.090 |
Why?
|
| Antithrombin III Deficiency | 1 | 2010 | 2 | 0.090 |
Why?
|
| Medicare | 3 | 2020 | 601 | 0.090 |
Why?
|
| Foramen Ovale, Patent | 1 | 2010 | 13 | 0.090 |
Why?
|
| Female | 5 | 2019 | 30581 | 0.090 |
Why?
|
| Cell Death | 1 | 2011 | 265 | 0.090 |
Why?
|
| Cortical Spreading Depression | 1 | 2009 | 10 | 0.080 |
Why?
|
| Hospital Units | 1 | 2009 | 8 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 286 | 0.080 |
Why?
|
| Health Care Sector | 1 | 2009 | 20 | 0.080 |
Why?
|
| Magnetic Field Therapy | 1 | 2008 | 3 | 0.080 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2008 | 11 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2020 | 343 | 0.080 |
Why?
|
| Functional Laterality | 2 | 2006 | 133 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2007 | 633 | 0.080 |
Why?
|
| Species Specificity | 1 | 2009 | 334 | 0.080 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 170 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 158 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2010 | 467 | 0.070 |
Why?
|
| Peptides | 1 | 2011 | 545 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 279 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2010 | 1047 | 0.070 |
Why?
|
| Injury Severity Score | 1 | 2007 | 103 | 0.070 |
Why?
|
| Equipment Design | 1 | 2008 | 313 | 0.070 |
Why?
|
| Virginia | 1 | 2007 | 16 | 0.070 |
Why?
|
| Radiography | 2 | 2006 | 505 | 0.070 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2090 | 0.070 |
Why?
|
| Benzenesulfonates | 1 | 2006 | 15 | 0.070 |
Why?
|
| Electrocardiography | 1 | 2009 | 521 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 701 | 0.070 |
Why?
|
| Brain Mapping | 1 | 2007 | 229 | 0.060 |
Why?
|
| Rats, Inbred WKY | 1 | 2005 | 11 | 0.060 |
Why?
|
| Body Temperature | 1 | 2005 | 44 | 0.060 |
Why?
|
| Drug Industry | 1 | 2005 | 40 | 0.060 |
Why?
|
| Legislation, Drug | 1 | 2005 | 18 | 0.060 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2005 | 24 | 0.060 |
Why?
|
| Equipment Safety | 1 | 2005 | 21 | 0.060 |
Why?
|
| Carbon Dioxide | 1 | 2005 | 74 | 0.060 |
Why?
|
| Drug Approval | 1 | 2005 | 27 | 0.060 |
Why?
|
| Models, Animal | 1 | 2005 | 219 | 0.060 |
Why?
|
| Cerebrovascular Disorders | 1 | 2005 | 72 | 0.060 |
Why?
|
| Risk | 1 | 2005 | 370 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2005 | 95 | 0.060 |
Why?
|
| Aspirin, Dipyridamole Drug Combination | 1 | 2003 | 3 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2005 | 485 | 0.060 |
Why?
|
| Software | 1 | 2007 | 363 | 0.060 |
Why?
|
| Dipyridamole | 1 | 2003 | 17 | 0.060 |
Why?
|
| Heart Rate | 1 | 2005 | 302 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2008 | 513 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 426 | 0.060 |
Why?
|
| Pharmaceutical Preparations | 1 | 2005 | 121 | 0.060 |
Why?
|
| Thrombosis | 1 | 2006 | 193 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2003 | 140 | 0.050 |
Why?
|
| Oxygen | 1 | 2005 | 301 | 0.050 |
Why?
|
| Recurrence | 1 | 2005 | 575 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2020 | 2429 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2005 | 770 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2003 | 132 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 925 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2003 | 188 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 347 | 0.050 |
Why?
|
| Adult | 2 | 2009 | 15609 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 252 | 0.050 |
Why?
|
| Disease Progression | 1 | 2005 | 1030 | 0.050 |
Why?
|
| Decision Making | 1 | 2004 | 382 | 0.050 |
Why?
|
| Water | 1 | 2002 | 294 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 1441 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 2316 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2007 | 3077 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2019 | 41 | 0.040 |
Why?
|
| Algorithms | 1 | 2004 | 981 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2018 | 70 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 59 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 278 | 0.040 |
Why?
|
| Skilled Nursing Facilities | 1 | 2018 | 84 | 0.040 |
Why?
|
| Mice | 1 | 2011 | 10194 | 0.040 |
Why?
|
| Urbanization | 1 | 2017 | 2 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2019 | 223 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 674 | 0.030 |
Why?
|
| Nursing Staff, Hospital | 1 | 2017 | 72 | 0.030 |
Why?
|
| Mechanical Thrombolysis | 1 | 2016 | 35 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2016 | 682 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 128 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 2444 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 855 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 336 | 0.020 |
Why?
|
| Silicon | 1 | 2006 | 20 | 0.020 |
Why?
|
| Sutures | 1 | 2006 | 33 | 0.020 |
Why?
|
| Perfusion | 1 | 2006 | 77 | 0.020 |
Why?
|
| Surface Properties | 1 | 2006 | 270 | 0.020 |
Why?
|